Safety and Efficacy of ALRV5XR in Women with Androgenetic Alopecia or Telogen Effluvium: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial

    June 2021 in “ EClinicalMedicine
    Peter D. Feldman, Klaus M. Fiebig, Charles Piwko, Boris M. Mints, Dennis Brown, Deborah J. Cahan, Jaime Guevara-Aguirre
    TLDR ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
    The study evaluated the safety and efficacy of ALRV5XR in women with androgenetic alopecia (AGA) or telogen effluvium (TE) through a 24-week randomized, double-blind, placebo-controlled trial involving 46 participants. Results showed significant improvements in terminal hair density, with increases ranging from 30.1 to 33.9 hairs/cm² in the ALRV5XR group compared to placebo. The treatment had a high response rate (66.7%) and was well-tolerated with no severe adverse events reported. ALRV5XR demonstrated superior efficacy over standard therapies, suggesting its potential as a new standard of care for female hair loss.
    Discuss this study in the Community →

    Research cited in this study

    22 / 22 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Related Research

    5 / 5 results